All agencies continue to be busy as we head into spring. We’ve had lots of exciting projects, including global product launches, continual team growth, new opportunities and worldwide collaborations within the US, EU and Asia Pacific.read more >>
Kerry Acheson joins us as Associate Editorial Director for Paragon, based in our brand new Macclesfield office. Kerry brings a wealth of experience to the team having worked in med comms for over 10 years across a range of therapy areas and projects. Kerry has a passion for people, both in training and developing writers, and in building relationships with clients and therapy experts. “I am looking forward to supporting the continued growth of Paragon and developing our new Macclesfield office!”read more >>
New Year = New Opportunities. A busy start to the New Year at Prime Global with lots of meetings and presentations to prepare for across a plethora of therapy areas – an exciting year ahead!read more >>
Amazing scientific sight…! The teams from ONYX and Only Oncology take a few moments on a recent business trip to admire the Atomium as it gleams against the bright blue Brussels sky!Prime Global 6 February, 2017
Picture + Amazing scientific sight! Thanks to ONYX and Only Oncology for sharing this fantastic pic taken on a recent business trip.read more >>
Valerie Moss attended the conference, “Publishing, medical writing and authorship: is more transparency needed?” This issue may also be known as ghostwriting. The definition of a ghostwriter is an Individual who inputs substantially, but acknowledged hardly at all for their work.
This event focused on discussing issues around authorship and the transparency of medical writing support, exploring industry practices and the use and recognition of writers.read more >>
Wow, what an end to a ‘BRILLIANT’ year! Our fantastic Prime Global people came together here in Knutsford to celebrate. Although, we missed our team mates in the New York and San Francisco offices.read more >>
Strimvelis, (autologous CD34+ cells transduced to express ADA) the first ex vivo stem cell gene therapy has been approved to treat patients with ADA-SCID (severe combined immunodeficiency due to adenosine deaminase deficiency). Children born with ADA-SCID do not have a heathy, fully functioning immune system and are unable to successfully combat everyday infections.
www.gsk.com › en-gb › Media › Press releasesread more >>
Prime hires new trio
The Prime Medical Group has taken on three new senior staff: VP, client services Karen Turner and principal medical writer Gauri Saal arrived earlier in the summer, while legal counsel Peter Townsend will start next week. Turner previously worked at Ashfield, the recent buyer of PR firm Pegasus, and Saal at market access firm PRMA Consulting, while Townsend currently works for solicitors Trower & Hamlins.read more >>
The Prime Medical Group recently announced three new hire who will reinforce an already impressive senior line-up. Find out more about Karen Turner (VP, Client Services), Gauri Saal (Principal Medical Writer) and Peter Townsend (Legal Counsel) here. (Source: Prime Medical Group, pharmiweb.com, 9/6/16)read more >>
Following a successful presentation at the Cell Therapy Manufacturing and Gene Therapy Congress in Brussels, Onyx has again had a strong presence at the prestigious World Orphan Drugs Congress in Washington. This emphasises Onyx strong and continuing commitment to the areas of orphan drugs, rare and ultra-rare diseases and regenerative medicine including cell and gene therapies.read more >>
We are excited to be speaking at the Cell Therapy Manufacturing & Gene Therapy Congress about the importance of Medical Communications for Gene Therapy. Find out more on KNect365 https://knect365bioprocessing.com/2016/01/29/prime-medical-group-value-medical-communications/read more >>